The potential of antioxidants to prevent atherosclerosis development and its clinical manifestations.
Pettersson
K S
KS
Department of Pharmacology CV, Astra Hässle, Mölndal, Sweden.
Ostlund-Lindqvist
A M
AM
Westerlund
C
C
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology*; D001158:Arteries / Q000187:drug effects / Q000502:physiology; D001161:Arteriosclerosis / Q000503:physiopathology / Q000517:prevention & control* / Q000628:therapy; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood / Q000737:chemistry; D008297:Male; D010084:Oxidation-Reduction; D011341:Probucol / Q000494:pharmacology; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology; D014810:Vitamin E / Q000494:pharmacology
D000924:Anticholesteremic Agents; D000975:Antioxidants; D008077:Lipoproteins, LDL; D014810:Vitamin E; D011341:Probucol